Navacaprant

Investigational antidepressant compound From Wikipedia, the free encyclopedia

Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140) is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression.[2][1][3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.[1] As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder.[1][4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.[5]

Other namesBTRX-140; CYM-53093; NMRA-140; NMRA-335140
Routes of
administrationOral[1]
Drug classκ-Opioid receptor antagonist
CAS Number
Quick facts Clinical data, Other names ...
Navacaprant
Clinical data
Other namesBTRX-140; CYM-53093; NMRA-140; NMRA-335140
Routes of
administration		Oral[1]
Drug classκ-Opioid receptor antagonist
Identifiers
  • 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard100.513.362 Edit this at Wikidata
Chemical and physical data
FormulaC25H32FN5O2
Molar mass453.562 g·mol−1
3D model (JSmol)
  • CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
  • InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
  • Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N
Close

See also

References

External links

Related Articles

Wikiwand AI